Your browser doesn't support javascript.
loading
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Knupp, Kelly G; Scheffer, Ingrid E; Ceulemans, Berten; Sullivan, Joseph; Nickels, Katherine C; Lagae, Lieven; Guerrini, Renzo; Zuberi, Sameer M; Nabbout, Rima; Riney, Kate; Agarwal, Anupam; Lock, Michael; Dai, David; Farfel, Gail M; Galer, Bradley S; Gammaitoni, Arnold R; Polega, Shikha; Davis, Ronald; Gil-Nagel, Antonio.
Afiliación
  • Knupp KG; University of Colorado, Children's Hospital Colorado, Aurora, Colorado, USA.
  • Scheffer IE; University of Melbourne, Austin Hospital and Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Ceulemans B; Department of Pediatric Neurology, Antwerp University Hospital, Antwerp, Belgium.
  • Sullivan J; University of California, San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, California, USA.
  • Nickels KC; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Lagae L; Member of the European Reference Network EpiCARE, Department of Pediatric Neurology, University of Leuven, Leuven, Belgium.
  • Guerrini R; Pediatric Neurology and Neurogenetics Unit, Anna Meyer Children's Hospital, University of Florence, Florence, Italy.
  • Zuberi SM; Stella Maris Foundation, Scientific Institute for Research and Health Care, Pisa, Italy.
  • Nabbout R; Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK.
  • Riney K; Reference Center for Rare Epilepsies, Necker-Sick Children University Hospital, Public Hospital Network of Paris, member of EpiCARE, Imagine Institute, Paris Cité University, Paris, France.
  • Agarwal A; Neuroscience Unit, Queensland Children's Hospital, South Brisbane, Queensland, Australia.
  • Lock M; School of Clinical Medicine, University of Queensland, St Lucia, Queensland, Australia.
  • Dai D; Zogenix (now a part of UCB), Emeryville, California, USA.
  • Farfel GM; Independent Consultant, Zogenix (now a part of UCB), Haiku, Hawaii, USA.
  • Galer BS; Syneos Health, Morrisville, North Carolina, USA.
  • Gammaitoni AR; Zogenix (now a part of UCB), Emeryville, California, USA.
  • Polega S; Zogenix (now a part of UCB), Emeryville, California, USA.
  • Davis R; Zogenix (now a part of UCB), Emeryville, California, USA.
  • Gil-Nagel A; Zogenix (now a part of UCB), Emeryville, California, USA.
Epilepsia ; 64(1): 139-151, 2023 01.
Article en En | MEDLINE | ID: mdl-36196777
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Lennox-Gastaut / COVID-19 Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Límite: Adolescent / Adult / Child / Humans Idioma: En Revista: Epilepsia Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Lennox-Gastaut / COVID-19 Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Límite: Adolescent / Adult / Child / Humans Idioma: En Revista: Epilepsia Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos